浸入科技 IMMR 深 沪
已收盘 08-01 16:00:00 美东时间
6.81
-0.160
-2.30%
华盛通- 最 高6.90
- 今 开6.86
- 成交量 43.04万股
- 最 低 6.765
- 昨 收 6.97
- 总市值 2.21亿
- 52周最高 11.00
- 市盈率 静 6.52
- 换手率 1.33%
- 52周最低 6.38
- 委 比 89.24%
- 总股本 3239.64万
- 历史最高 16.97
- 量 比 0.94
- 振 幅 1.94%
- 历史最低 3.415
- 每 手 1
- 风险率 1.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immersion Announces Quarterly Cash Dividend Declaration
Immersion ( ($IMMR) ) has provided an announcement. On July 8, 2025, Immersion ...
07-09 04:56
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
Immuneering Corporation reported positive Phase 2a data for atebimetinib in combination with modified Gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. The treatment showed 94% overall survival (OS) and 72% progression-free survival (PFS) at 6 months, with a 39% overall response rate and 81% disease control rate. Atebimetinib demonstrated a favorable tolerability profile. The company plans a pivotal trial for 2026 and will host...
06-17 10:00
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
<p>Immuneering Corporation announced it will host a conference call and live webcast on June 17, 2025, at 8:00 am ET, to update on its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The webcast will be available on the company's Investor Relations website. IMM-1-104 is an oral, once-daily MEK inhibitor targeting MAPK pathway-driven tumors like pancreatic cancer. For more information, visit www.immuneering.c...
06-16 12:00
Immuneering to Present at the Jefferies Global Healthcare Conference
**Immuneering Corporation to Present at Jefferies Global Healthcare Conference** Immuneering Corporation, a clinical-stage oncology company focused on developing effective and well-tolerated cancer therapies, will present at the Jefferies Global Healthcare Conference on June 5, 2025. The presentation will include a company overview, pipeline updates, and business strategy discussions. Key executives, including CEO Ben Zeskind, CMO Igor Matushan...
05-29 12:00
美股大行评级 | 花旗：首予BioNTech SE(BNTX)"买入"评级，目标价145美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1107226114384474112.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity：维持Zevra Therapeutics(ZVRA)"买入"评级，目标价从23美元升至25美元</p> <p>• Benchmark：维持E W Scripps(SSP)"买入"评级，目
03-14 09:45
Immersion Non-GAAP EPS of $0.63 beats by $0.08, revenue of $474.76M beats by $338.7M
Immersion press release (NASDAQ:IMMR): Q3 Non-GAAP EPS of $0.63 beats by $0.08. Revenue of $474.76M (compared to $9.5 million in the three months ended September 30, 2023) beats by $338.7M. More on Im...
03-12 20:39
Immersion Q3 EPS $0.47, Sales $474.76M
Immersion (NASDAQ:IMMR) reported quarterly earnings of $0.47 per share. The company reported $474.76 million in sales this quarter.
03-12 20:34
美股大行评级 | 潜在升幅410%！TransCode Therapeutics获机构大幅上调目标价至20美元
<span> <meta content="no-referrer" name="referrer"></span><img src="https://r.hstong.com/public/cms/images/2024/12/19/20241219084201089.png" referrerpolicy="no-referrer"><figure class="table" style="overflow-x: scroll;"> <table> <tbody> <tr> <td>标的</td> <td>代码</td> <td>评级</td> <td>目标价</td> <td>当前价</td> <td>潜在涨跌幅</td> <td>机构名称</td> </tr> <tr> <td>TransCode Therapeutics Inc Ordinary Shares</td> <td
2024-12-19 09:43
Earnings week ahead: CRWD, DELL, ZM, WDAY, HPQ, M, BBY and more
Earnings season is winding down, but the holiday-shortened Thanksgiving week still brings quarterly updates from several high-profile companies. Tech leaders like CrowdStrike (CRWD), Zoom Video Commun...
2024-11-24 21:01
Immersion Stock Is Surging Wednesday: What's Behind The Move?
Immersion reported second-quarter revenue of $99.42 million, up from $6.98 million in the prior year's period. The haptics technology company reported adjusted earnings of $1.14 per share, up from 26 cents in the prior year's quarter, per Benzinga Pro.
2024-08-21 21:28
